PIK3CA and head and neck squamous cell carcinoma: These results together suggest that the combination of Mitomycin C and Onalespib may offer a promising therapeutic strategy specifically for PIK3CA-driven HNSCC, further underscoring our genetically-defined, cross-species organoid models as valid, clinically-relevant platforms for drug-gene association discovery.